Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Fagan

Showing results (91-100 of 279) with videos related to

Pageof 28
Sort By:
Neurology|August 20, 2017
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adultsGe Li, Cynthia L Mayer, Daniel Morelli, et al.
JAMA Neurology|July 26, 2016
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and TauopathyLiang Wang, Tammie L Benzinger, Yi Su, et al.
Journal of Alzheimer'S Disease : JAD|February 18, 2009
Performance characteristics of plasma amyloid-beta 40 and 42 assaysOlivia I Okereke, Weiming Xia, Michael C Irizarry, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2017
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 yearsSuzanne E Schindler, Courtney L Sutphen, Charlotte Teunissen, et al.
Neurobiology of Aging|May 9, 2017
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer diseaseSuzanne E Schindler, Mateusz S Jasielec, Hua Weng, et al.
Molecular Neurodegeneration|April 27, 2012
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjectsSaori Hata, Miyako Taniguchi, Yi Piao, et al.
Annals of Neurology|July 12, 2016
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer diseaseAndrei G Vlassenko, Lena McCue, Mateusz S Jasielec, et al.
Annals of Neurology|May 1, 2016
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluidYo-El S Ju, Mary Beth Finn, Courtney L Sutphen, et al.
The American Journal of Pathology|October 7, 2004
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosisAnne M Fagan, Erin Christopher, Jennie W Taylor, et al.
JAMA Neurology|August 21, 2013
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivityLiang Wang, Matthew R Brier, Abraham Z Snyder, et al.
Pageof 28

Showing results (91-100 of 279) with videos related to

Sort By:
Pageof 28
Neurology|August 20, 2017
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adultsGe Li, Cynthia L Mayer, Daniel Morelli, et al.
JAMA Neurology|July 26, 2016
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and TauopathyLiang Wang, Tammie L Benzinger, Yi Su, et al.
Journal of Alzheimer'S Disease : JAD|February 18, 2009
Performance characteristics of plasma amyloid-beta 40 and 42 assaysOlivia I Okereke, Weiming Xia, Michael C Irizarry, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2017
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 yearsSuzanne E Schindler, Courtney L Sutphen, Charlotte Teunissen, et al.
Neurobiology of Aging|May 9, 2017
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer diseaseSuzanne E Schindler, Mateusz S Jasielec, Hua Weng, et al.
Molecular Neurodegeneration|April 27, 2012
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjectsSaori Hata, Miyako Taniguchi, Yi Piao, et al.
Annals of Neurology|July 12, 2016
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer diseaseAndrei G Vlassenko, Lena McCue, Mateusz S Jasielec, et al.
Annals of Neurology|May 1, 2016
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluidYo-El S Ju, Mary Beth Finn, Courtney L Sutphen, et al.
The American Journal of Pathology|October 7, 2004
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosisAnne M Fagan, Erin Christopher, Jennie W Taylor, et al.
JAMA Neurology|August 21, 2013
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivityLiang Wang, Matthew R Brier, Abraham Z Snyder, et al.
Pageof 28